Literature DB >> 1746563

Interpreting nonsignificant outcomes of heterogeneity tests in gene mapping.

C Mérette, T Lehner, J Ott.   

Abstract

Mesh：

Year:  1991        PMID： 1746563      PMCID： PMC1686468     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN： 0002-9297            Impact factor:   11.025


× No keyword cloud information.
  5 in total

1.  TESTING FOR HETEROGENEITY OF RECOMBINATION FRACTION VALUES IN HUMAN GENETICS.

Authors:  C A SMITH
Journal:  Ann Hum Genet       Date:  1963-11       Impact factor: 1.670

2.  The detection and estimation of linkage between the genes for elliptocytosis and the Rh blood type.

Authors:  N E MORTON
Journal:  Am J Hum Genet       Date:  1956-06       Impact factor: 11.025

3.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

4.  When was a "negative" clinical trial big enough? How many patients you needed depends on what you found.

Authors:  A S Detsky; D L Sackett
Journal:  Arch Intern Med       Date:  1985-04

5.  Localizing multiple X chromosome-linked retinitis pigmentosa loci using multilocus homogeneity tests.

Authors:  J Ott; S Bhattacharya; J D Chen; M J Denton; J Donald; C Dubay; G J Farrar; G A Fishman; D Frey; A Gal
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205
  5 in total
  2 in total

1.  High-resolution mapping of the X-linked hypohidrotic ectodermal dysplasia (EDA) locus.

Authors:  J Zonana; M Jones; D Browne; M Litt; P Kramer; H W Becker; N Brockdorff; S Rastan; K P Davies; A Clarke
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

2.  Autosomal dominant retinitis pigmentosa: no evidence for nonallelic genetic heterogeneity on 3q.

Authors:  R Kumar-Singh; H Wang; P Humphries; G J Farrar
Journal:  Am J Hum Genet       Date:  1993-02       Impact factor: 11.025
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.